VeriStrat (R) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib

J. L. Kuiper, J. S. W. Lind, H. J. M. Groen, J. Roder, J. Grigorieva, H. Roder, A. M. C. Dingemans, E. F. Smit

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1820-1825
JournalBritish Journal of Cancer
Issue number11
Publication statusPublished - 20 Nov 2012


  • lung cancer
  • proteomics
  • erlotinib
  • sorafenib
  • serum biomarker
  • personalised therapy

Cite this